8-K: Incannex Receives IRB Approval for Phase 2/3 Sleep Apnea Clinical Trial

Incannex Healthcare has received Institutional Review Board (IRB) approval to begin its Phase 2/3 clinical trial for IHL-42X in patients with obstructive sleep apnea (OSA).

Summary

• Incannex Healthcare has secured IRB approval for its Phase 2/3 clinical trial of IHL-42X for obstructive sleep apnea (OSA).
• The trial, named RePOSA, will assess the safety and efficacy of IHL-42X in patients who are intolerant, non-compliant, or new to positive airway pressure (PAP) therapy.
• The study includes a four-week Phase 2 dose-ranging trial to determine the optimal dose of IHL-42X, followed by a 52-week Phase 3 trial comparing the optimal dose to its component APIs and a placebo.
• The trial aims to recruit at least 560 patients, with 355 receiving IHL-42X.
• The study is registered on clinicaltrials.gov with identification code NCT06146101.
• The Phase 2/3 trial will be conducted at 24 sites in the United States, 13 in Germany, 4 in Spain, and 2 in Finland.
• A previous Phase 2 study showed that IHL-42X reduced the apnea hypopnea index (AHI) by more than 50% at the optimal dose, with 62.5% of patients experiencing a reduction in AHI of greater than 50% and 25% of patients experiencing a reduction in AHI of greater than 80%.

Sentiment

Score: 8

Explanation: The document is positive due to the IRB approval and the promising results from the previous Phase 2 study. The company is moving forward with a significant clinical trial, which is a positive development for investors.

Positives

• IRB approval is a key step in activating clinical trial sites for the RePOSA study.
• The study design facilitates a seamless transition between Phase 2 and Phase 3, reducing downtime.
• The previous Phase 2 study showed promising results with IHL-42X significantly reducing AHI and improving other sleep metrics.
• IHL-42X was well tolerated in the previous Phase 2 study.
• The global market for OSA detection and treatment is approximately US$10 billion per annum and growing.

Negatives

• The document does not explicitly mention any negative aspects of the trial or the drug.

Risks

• The success of the clinical trial is not guaranteed, and the drug may not receive regulatory approval.
• Patient recruitment and retention may pose challenges.
• There is a risk that the drug may not be as effective or well-tolerated in the larger Phase 2/3 trial as it was in the Phase 2 study.
• The company is subject to regulatory risks associated with drug development and approval.

Future Outlook

Incannex anticipates greatly improved treatment compliance and outcomes from a pharmaceutical product, such as IHL-42X, subject to further clinical assessment and approval from regulators. The company is pursuing U.S. FDA approval and registration for each drug and therapy under development.

Management Comments

• Incannex is pleased to announce that an independent Institutional Review Board (IRB) has approved the protocol for the Company's Phase 2/3 clinical trial.
• Incannex anticipates greatly improved treatment compliance and outcomes from a pharmaceutical product, such as IHL-42X, subject to further clinical assessment and approval from regulators.

Industry Context

The announcement is significant as there are currently no pharmacotherapy treatments available for OSA, with the current standard of care being PAP machines, which have low patient compliance. Incannex is aiming to address this unmet need with IHL-42X.

Comparison to Industry Standards

• The current standard of care for OSA is Positive Airway Pressure (PAP) therapy, which has low patient compliance due to discomfort.
• Incannex is developing a pharmaceutical alternative, IHL-42X, which aims to improve treatment compliance and outcomes.
• The company is targeting a large market, with approximately 30 million adults in the United States alone affected by OSA.
• The economic burden of undiagnosed sleep apnoea in the US is estimated at US$149.6 billion per annum, highlighting the significant need for effective treatments.

Stakeholder Impact

• Shareholders will benefit from the progress of the clinical trial and the potential for a new treatment for OSA.
• Patients with OSA may benefit from a new treatment option if the trial is successful.
• Employees of Incannex will be involved in the clinical trial process.
• The company's partners will be involved in the development and commercialization of the drug.

Next Steps

• The U.S.-based sites will proceed with site-specific approval.
• Patient recruitment will commence at the 24 sites in the United States, 13 in Germany, 4 in Spain and 2 in Finland.
• The Phase 2 dose-ranging trial will determine the optimal dose of IHL-42X.
• The Phase 3 factorial trial will compare the optimal dose of IHL-42X to its component APIs and a placebo.

Key Dates

Keywords

Obstructive Sleep Apnea, OSA, IHL-42X, Clinical Trial, Phase 2/3, IRB Approval, RePOSA, Apnea Hypopnea Index, AHI, Dronabinol, Acetazolamide, Pharmacotherapy